GNP联合化疗治疗难治复发非霍奇金淋巴瘤的疗效分析  

Effi cacy of GNP combined chemotherapy in treatment for refractory and relapse non-hodgkin lymphoma

作　　者：王志红[1] 周宏伟[1] 刘默[1] 曹志刚[1] 周敏航[1] 邢丽[1] 冯少美 古永建 彭朝津[1] 孙君重[1] 杨清明[1] 

机构地区：[1]解放军总医院第一附属医院老年血液肿瘤科,北京100048

出　　处：《解放军医学院学报》2015年第8期797-800,共4页Academic Journal of Chinese PLA Medical School

摘　　要：目的观察GNP（吉西他滨、奈达铂联合甲泼尼松龙）联合化疗治疗难治复发非霍奇金淋巴瘤的疗效。方法对本科2009年1月-2013年7月自愿接受GNP化疗的30例难治复发非霍奇金淋巴瘤住院患者进行疗效及不良反应的回顾性分析。其中难治12例,复发13例,进展5例。类型包括B细胞淋巴瘤18例,T细胞或NK/T细胞淋巴瘤12例。接受治疗的中位周期数为2（2-7）个疗程。结果 2个周期GNP治疗,显示完全缓解（complete remission,CR）3例,部分缓解（partial remission,PR）20例,稳定（stable disease,SD）7例。总反应率（over response rate,ORR）为76.7%,1年总生存率（over survival,OS）为86.7%,无进展生存（progression-free survival,PFS）占40%,中位PFS为10个月（95%CI：5.8-14.2个月）。不良反应轻,耐受性良好。结论 GNP联合化疗治疗难治复发非霍奇金淋巴瘤可以取得良好的疗效。Objective To observe the efficacy of GNP（gemcitabine, nedaplatin, methyl prednisolone） combined chemotherapy in treatment for refractory and relapse non-hodgkin lymphoma（NHL）. Methods The efficacy and adverse responses of 30 patients with refractory and relapse NHL who had voluntarily received GNP chemotherapy in our hospital from January 2009 to July 2013 were retrospectively analyzed. Of the 30 cases, 12 cases were refractory, 13 cases were relapse and 5 cases were progression. 18 cases were B cell lymphoma and 12 cases were T or NK/T cell lymphoma. The median circles of therapy-receiving were 2 circles（2-7 circles）. Results The efficacy of GNP combined chemotherapy in treatment for refractory and relapse NHL showed complete remission（CR） in 3 cases, partial remission（PR） in 20 cases, stable disease（SD） in 7 cases. The over response rate（ORR） was 76.7%, and the over survival rate for 1 year reached 86.7%. The progression free survival（PFS） reached 40% with the median PFS of 10 months（95% CI for 5.8- 14.2 months）. The adverse responses were slight and the endurement was fine. Conclusion There is favorable efficacy for GNP combined chemotherapy in treatment for refractory and relapse non-hodgkin lymphoma.

关 键 词：吉西他滨 奈达铂 复发难治 非霍奇金淋巴瘤 

分 类 号：R733.4[医药卫生—肿瘤] R730.53[医药卫生—临床医学]